TY - JOUR
T1 - The protective effect of farm milk consumption on childhood asthma and atopy: The GABRIELA study
AU - Loss, Georg
AU - Apprich, Silvia
AU - Waser, Marco
AU - Kneifel, Wolfgang
AU - Genuneit, Jon
AU - Bu¨chele, Gisela
AU - Weber, Juliane
AU - Sozanska, Barbara
AU - Danielewicz, Hanna
AU - Horak, Elisabeth
AU - Joost van Neerven, R. J.
AU - Heederik, Dick
AU - Lorenzen, Peter C.
AU - von Mutius, Erika
AU - Braun-Fahrla¨nder, Charlotte
AU - Boznanski, Andrzej
AU - Cookson, William
AU - Cullinan, Paul
AU - Debin´ska, Anna
AU - Depner, Martin
AU - Ege, Markus
AU - Frey, Urs
AU - Fuchs, Oliver
AU - Hyva¨rinen, Anne
AU - Illi, Sabina
AU - Kabesch, Michael
AU - Kovacs, Katalin
AU - Kosmeda, Aleksandra
AU - Latzin, Philipp
AU - Lauener, Roger
AU - MacNeill, Stephanie
AU - Morass, Bernhard
AU - Normand, Anne Ce´cile
AU - Piarroux, Renaud
AU - Rintala, Helena
AU - Rochat, Mascha K.
AU - Sitaridis, Nikolaos
AU - Strachan, David
AU - Strunz-Lehner, Christine
AU - Sudre, Bertrand
AU - Waser, Marco
AU - Wouters, Inge M.
N1 - Funding Information:
Supported by a European Union Research grant under the FP6-LifeSCIHEALTH Integrated Program LSH-2004-1.2.5-1 (contract no. 018996 ).
Funding Information:
Disclosure of potential conflict of interest: J. Weber, B. Sozanska, H. Danielewicz, A Boznanski, A. Dębińska, M. Depner, A. Kosmęda, and C. Strunz-Lehner have received research support from the European Commission . D. Heederik and I. M. Wouters have received research support from the European Union . E. von Mutius is a consultant for Novartis, GlaxoSmithKline, ALK-Abelló, and Protectimmun; has received a speaker's fee from InfectoPharm; has received research support from Airsonett AB ; is a member of the Expert Panel for UK Research Excellence Framework; and is an Associate Editor for the Journal of Allergy and Clinical Immunology. M. Ege has received research support from the European Commission and the Deutsche Forschungsgemeinschaft (DFG) . M. Kabesch has financial interests in Roxall, GlaxoSmithKline, Novartis, Sanofi-Aventis, Allergopharma, and AstraZeneca GmbH and has received research support from DFG, BMBF, and the European Union . The rest of the authors have declared that they have no conflict of interest.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2011/10/1
Y1 - 2011/10/1
N2 - Background: Farm milk consumption has been identified as an exposure that might contribute to the protective effect of farm life on childhood asthma and allergies. The mechanism of action and the role of particular constituents of farm milk, however, are not yet clear. Objective: We sought to investigate the farm milk effect and determine responsible milk constituents. Methods: In rural regions of Germany, Austria, and Switzerland, a comprehensive questionnaire about farm milk consumption and other farm-related exposures was completed by parents of 8334 school-aged children, and 7606 of them provided serum samples to assess specific IgE levels. In 800 cow's milk samples collected at the participants' homes, viable bacterial counts, whey protein levels, and total fat content were analyzed. Asthma, atopy, and hay fever were associated to reported milk consumption and for the first time to objectively measured milk constituents by using multiple regression analyses. Results: Reported raw milk consumption was inversely associated to asthma (adjusted odds ratio [aOR], 0.59; 95% CI, 0.46-0.74), atopy (aOR, 0.74; 95% CI, 0.61-0.90), and hay fever (aOR, 0.51; 95% CI, 0.37-0.69) independent of other farm exposures. Boiled farm milk did not show a protective effect. Total viable bacterial counts and total fat content of milk were not significantly related to asthma or atopy. Increased levels of the whey proteins BSA (aOR for highest vs lowest levels and asthma, 0.53; 95% CI, 0.30-0.97), α-lactalbumin (aOR for interquartile range and asthma, 0.71; 95% CI, 0.52-0.97), and β-lactoglobulin (aOR for interquartile range and asthma, 0.62; 95% CI, 0.39-0.97), however, were inversely associated with asthma but not with atopy. Conclusions: The findings suggest that the protective effect of raw milk consumption on asthma might be associated with the whey protein fraction of milk.
AB - Background: Farm milk consumption has been identified as an exposure that might contribute to the protective effect of farm life on childhood asthma and allergies. The mechanism of action and the role of particular constituents of farm milk, however, are not yet clear. Objective: We sought to investigate the farm milk effect and determine responsible milk constituents. Methods: In rural regions of Germany, Austria, and Switzerland, a comprehensive questionnaire about farm milk consumption and other farm-related exposures was completed by parents of 8334 school-aged children, and 7606 of them provided serum samples to assess specific IgE levels. In 800 cow's milk samples collected at the participants' homes, viable bacterial counts, whey protein levels, and total fat content were analyzed. Asthma, atopy, and hay fever were associated to reported milk consumption and for the first time to objectively measured milk constituents by using multiple regression analyses. Results: Reported raw milk consumption was inversely associated to asthma (adjusted odds ratio [aOR], 0.59; 95% CI, 0.46-0.74), atopy (aOR, 0.74; 95% CI, 0.61-0.90), and hay fever (aOR, 0.51; 95% CI, 0.37-0.69) independent of other farm exposures. Boiled farm milk did not show a protective effect. Total viable bacterial counts and total fat content of milk were not significantly related to asthma or atopy. Increased levels of the whey proteins BSA (aOR for highest vs lowest levels and asthma, 0.53; 95% CI, 0.30-0.97), α-lactalbumin (aOR for interquartile range and asthma, 0.71; 95% CI, 0.52-0.97), and β-lactoglobulin (aOR for interquartile range and asthma, 0.62; 95% CI, 0.39-0.97), however, were inversely associated with asthma but not with atopy. Conclusions: The findings suggest that the protective effect of raw milk consumption on asthma might be associated with the whey protein fraction of milk.
UR - http://www.scopus.com/inward/record.url?scp=80053575852&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2011.07.048
DO - 10.1016/j.jaci.2011.07.048
M3 - Journal articles
C2 - 21875744
AN - SCOPUS:80053575852
SN - 0091-6749
VL - 128
SP - 766
EP - 773
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 4
ER -